From scientific discovery and clinical research to manufacturing and market access, the next era of biotech innovation may belong to ecosystems that collaborate rather than compete.
Walking the BIO International Convention floor in San Diego, two national pavilions stand out for more than their size.
The United Kingdom and India have both arrived with a clear purpose. Their presence is not simply about attracting investment, showcasing companies, or promoting exports.
It reflects a broader reality in reshaping global health innovation: the future will increasingly depend on connected ecosystems rather than isolated hubs of excellence.
For decades, discussions about biotechnology leadership focused on competition among innovation hubs.
Boston, San Diego, London, Basel, Singapore, and other centers sought to distinguish themselves through scientific output, venture investment, clinical research capabilities, or manufacturing strength.
While those advantages remain important, BIO 2026 suggests that a new dynamic is emerging.
The most successful innovation ecosystems may not be those that attempt to do everything themselves, but rather those that effectively connect complementary strengths across geographies.
The significant presence of the United Kingdom and India offers an opportunity to examine how this new model is taking shape and why it matters to investors, researchers, health systems, and, perhaps most importantly, to patients worldwide.
“Europeans are increasingly recognising the importance of India as a biotech and health hub. The country’s ability to access vast integrated databases will be a key advantage in the big data era,” comments Mark Chataway, managing partner, FINN Partners, a global voice in health policy and access.
“Its extraordinary IT research capacity is finally coming together with long-established centers of medical excellence to build world-class biotech capabilities atop the world’s largest population,” he adds.
From National Champions to Global Networks
The United Kingdom arrives at BIO with substantial advantages.
The Golden Triangle of London, Oxford, and Cambridge remains one of the world’s most concentrated life sciences clusters.
Leading universities, academic medical centers, research institutions, investors, pharmaceutical companies, and health technology innovators operate within a highly interconnected geography that continues to generate scientific breakthroughs and commercial opportunities.
The country’s strengths extend beyond discovery science.
The National Health Service, despite pressing challenges, provides a unique environment for clinical research, population health studies, real-world evidence generation and innovation validation.
Few countries can offer innovators access to a health system capable of supporting research and data collection with such a diverse population and at such a scale.
Combined with a supportive regulatory environment and a growing commitment to life sciences investment, the UK continues to attract global attention as a destination for health innovation.
However, the message Britain appears to be sending at BIO extends beyond its existing strengths.
The UK is increasingly positioning itself as a global connector. Rather than simply promoting its research institutions or startup ecosystem, it is making the case that it can serve as a bridge linking scientific discovery, clinical development, regulatory expertise, commercialisation and global collaboration.
The country’s evolving life sciences strategy reflects an understanding that the next generation of breakthroughs will require cross-border, cross-disciplinary partnerships.
This shift mirrors a broader reality across health.
The challenges confronting health systems: aging populations, chronic disease, workforce shortages, rising costs, and persistent health inequities cannot be solved by any single organisation or nation. Innovation increasingly depends on networks that combine expertise, investment, manufacturing capacity, digital capabilities and market access.
Why the UK and India Matter Together
India’s presence at BIO reinforces this emerging model.
Long recognised as a global leader in pharmaceutical manufacturing and vaccine production, largely for generic medications, India is rapidly expanding its influence across biotechnology, digital health, artificial intelligence, clinical research, and venture-backed innovation.
The country is investing heavily in research infrastructure while leveraging its deep pool of engineering, software, and data science talent.
These resources have become so evident that major biopharma companies such as Bristol Myers Squibb, MSD, Novartis, and others have established Global Capability Centers (GCCs) in the high-tech city of Hyderabad.
India also offers something that many mature innovation ecosystems increasingly seek: scale.
Its large and diverse population, expanding health sector, growing research capabilities, and manufacturing capacity create opportunities that are difficult to replicate elsewhere.
As health care becomes more data-driven and globally connected, these advantages become increasingly valuable.
Viewed together, the strengths of the UK and India appear remarkably complementary.
The UK contributes scientific discovery, translational research, academic medicine, clinical validation, regulatory expertise, and access to global capital.
India contributes manufacturing scale, engineering excellence, digital innovation, operational efficiency and a rapidly growing and needed market.
Neither country alone is a complete innovation ecosystem. Together, however, they begin to resemble a powerful innovation corridor that spans research, development, production, and commercialisation.
“India’s cooperation with the UK builds on long-standing cultural, personal and commercial ties between the two countries,” comments Chataway.
The historical links are occasionally painful, but we, at least, understand one another well. So many families now span the UK and India, and major companies such as Tata and Unilever create parallel business links,” .
Perhaps the most visible example of UK-India biotechnology collaboration emerged in June 2020, when AstraZeneca and the University of Oxford reached an agreement with the Serum Institute of India to manufacture and distribute up to one billion doses of the Oxford COVID-19 vaccine for low- and middle-income countries.
The partnership combined British scientific discovery with Indian manufacturing scale, demonstrating how complementary capabilities across borders can accelerate both innovation and patient access.
This relationship is particularly important at a moment when biotechnology companies face growing pressure to accelerate development timelines while controlling costs and expanding access.
The ability to combine world-class research environments with scalable development and manufacturing capabilities creates strategic advantages for both countries and for the organisations that choose to partner with them.
In April 2026, Bengaluru-based C-CAMP and Imperial College London launched the Indo-UK Life Sciences Innovation Corridor, a five-year initiative designed to promote joint research, startup collaboration, technology transfer, and talent exchange.
The agreement reflects a growing commitment by both countries to build integrated innovation opportunities.
The New Measure of Biotech Leadership
The significance of the UK and India BIO 2026 pavilions highlights a broader shift in how leadership in biotechnology may be defined during the coming decade.
Historically, innovation ecosystems were often measured by the number of startups created, venture capital invested, patents filed, or scientific papers published.
Those metrics remain important, but they tell only part of the story. Increasingly, success will depend on how effectively ecosystems connect discovery, clinical development, manufacturing, data, digital technologies, capital and patient access.
Investors are already adapting to this reality. Pharmaceutical companies routinely build global development strategies. Digital health innovators seek research partners, talent, and markets across multiple continents.
Governments are recognising that attracting innovation requires more than funding research; it requires creating environments where ideas can move efficiently from laboratory benches to patient bedsides.
The United States remains the gravitational centre of global biotechnology, and BIO remains the industry’s premier gathering place.
What makes the UK and India presence worth watching is that both countries appear to recognise that future success will not come from replicating Boston, San Diego, or Silicon Valley.
Instead, they are pursuing a model built on connectivity, collaboration and complementary strengths.
For patients, this approach offers the potential for faster access to new therapies, diagnostics and digital health tools.
For investors, it creates opportunities to participate in broader and potentially more resilient value chains.
For health-sector leaders, it provides new pathways to accelerate innovation while addressing increasingly complex global health challenges.
The future of biotechnology will undoubtedly continue to be shaped by scientific excellence that addresses unmet patient needs. Yet excellence alone may no longer be sufficient.
As the UK and India demonstrate through their presence at BIO 2026, perhaps the next era of health innovation may belong not to the largest or wealthiest ecosystem, but to the one best able to draw on collaborative strengths.
That may prove to be among the more important lessons emerging from San Diego this week.
Gil Bashe is a Health Tech World correspondent, Medika Life Editor-in-Chief, and author of the bestseller “Healing the Sick Care System: Why People Matter
Photo Credit: Author at the BIO International 2026 Convention
